Imaging patients with kidney disease: How do we approach contrast-related toxicity?

American Journal of the Medical Sciences

Volumn 341, Issue 3, 2011, Pages 215-221

  Perazella, Mark A ^a   Reilly, Robert F ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Diagnostic imaging; Gadolinium; Kidney disease; Nephrogenic systemic fibrosis; Radiocontrast induced nephropathy

Indexed keywords

BICARBONATE; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; IODINATED CONTRAST MEDIUM; ISOTONIC SOLUTION;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC VALUE; ECHOGRAPHY; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFORMED CONSENT; KIDNEY DISEASE; LUNG EDEMA; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL PRACTICE; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; PATIENT ASSESSMENT; PATIENT SAFETY; RADIOCONTRAST INDUCED NEPHROPATHY; RECURRENT DISEASE; RENOGRAPHY; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE;

EID: 79952071552     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181f016e6     Document Type: Review

References (57)

1. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-93. (Pubitemid 32938907)
2. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
3. Dawson P, Punwani S. Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients. Semin Dial 2008;21: 160-5.
4. Lind Ramskov K, Thomsen HS. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function? Acat Radiol 2009;26:1-3.
5. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009;4:461-9.
6. Perazella MA. Radiocontrast-induced nephropathy: an update. Minerva Urol Nefrol 2009;61:215-33.
7. Weisbord SD, Mor MK, Resnick AL, et al. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol 2008;3:1274-81.
8. Mitchell AM, Jones AE, Tumlin JA, et al. Incidence of contrastinduced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol 2010;5:4-9.
9. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996;275:1489-94. (Pubitemid 26140761)
10. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75. (Pubitemid 27506242)
11. Gruber L, Mintz GGS, Mehran R, et al. The prognostic implications of renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existing chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-8.
12. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneously coronary intervention. Circulation 2002;105:2259-64. (Pubitemid 34535335)
13. Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009;4:1162-9.
14. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
15. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006;18: 614-7. (Pubitemid 44607415)
16. Marckmann P, Skov L, Rossen, et al. Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62. (Pubitemid 44300951)
17. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-7.
18. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roent 2007;188:586-92. (Pubitemid 46167763)
19. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007;42:139-45. (Pubitemid 46104895)
20. Kallen AJ, Jhung MA, Cheng S, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-75. (Pubitemid 351711602)
21. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243: 148-57. (Pubitemid 46579705)
22. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-8. (Pubitemid 350202540)
23. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: Incidence, associations, and effect of risk factor assessmentreport of 33 cases. Radiology 2009;250:371-7.
24. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168-75. (Pubitemid 47417800)
25. Othersen JB, Maize JC, Woolson RF, et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007;22:3179-85. (Pubitemid 350202590)
26. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007;26:1198-203. (Pubitemid 350058286)
27. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol 2007;57: 105-11. (Pubitemid 46899273)
28. Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009;53:133-7.
29. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248: 807-16.
30. Agarwal R, Brunelli SM, Williams K, et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63.
31. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-6. (Pubitemid 46017000)
32. Boyd AC, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30. (Pubitemid 44969309)
33. High WA, Eng M, Ayers RA, et al. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:1-2.
34. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3: 968-75.
35. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66:230-4.
36. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008;3:747-51.
37. Prince MR, Zhang HL, Prowda JC, et al. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics 2009;29: 1565-74.
38. Martin DR, Krishnamoorthy SK, Kalb B, et al. J Magn Reson Imaging 2010;31:440-6.
39. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging 2009;30:1240-8.
40. Perazella MA. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? Clin J Am Soc Nephrol 2009;3:649-51.
41. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. Am J Roentgenol 2008;190:736-41. (Pubitemid 351304519)
42. Bahrami S, Raman SS, Sauk S, et al. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. J Comput Assist Tomogr 2009;33:819-23.
43. Heinz-Peer G, Neruda A, Watschinger B, et al. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol 2010;76:129-34.
44. Chapman A, Grantham JJ, Guay-Woodford LM, et al. Absence of NSF following gadolinium exposure in ADPKD individuals with stable CKD. [Abstract]. J Am Soc Nephrol 2007;18:837A.
45. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-4.
46. Chrysochou C, Power A, Shurrab AE, et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 2010;5:484-9.
47. Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25.
48. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502. (Pubitemid 28303906)
49. Krumme B. Renal Doppler sonography-update in clinical nephrology. Nephron Clin Pract 2006;103:c24-8.
50. Zhang HL, Sos TA, Winchester PA, et al. Renal artery stenosis: imaging options, pitfalls, and concerns. Prog Card Dis 2009;52: 209-19.
51. Gao J, Shih G, Auh YH, et al. Pitfalls and sources of error of error of color duplex sonography in screening for renovascular hypertension. Int J Nephrol Urol 2010;2:212-23.
52. Wilson SR, Greenbaum LD, Goldberg BB. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? Am J Radiol 2009;193:55-60.
53. Neuwelt EA, Hamilton BE, Varallyay CG, et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009;75:465-74.
54. Wilson GJ, Maki JH. Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. Magn Reson Imaging Clin N Am 2009;17: 13-27.
55. Maki JH, Wilson GJ, Eubank WB, et al. Steady-state free precession MRA of the renal arteries: breath-hold and navigator-gated techniques vs. CE-MRA. J Magn Reson Imaging 2007;26:966-73. (Pubitemid 47548158)
56. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254:47-66.
57. Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities. Radiology 2009;253:689-96.